{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:31:01Z","timestamp":1786739461675,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2014,4,15]],"date-time":"2014-04-15T00:00:00Z","timestamp":1397520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,4,15]]},"abstract":"<jats:p>\n                    Single-chain variable domain fragment (scFv) 637 is an antigen-specific scFv of myasthenia gravis. In this study, scFv and human serum albumin genes were conjugated and the fusion protein was expressed in\n                    <jats:italic toggle=\"yes\">Pichia pastoris<\/jats:italic>\n                    . The affinity of scFv-human serum albumin fusion protein to bind to acetylcholine receptor at the neuromuscular junction of human intercostal muscles was detected by immunofluorescence staining. The ability of the fusion protein to block myasthenia gravis patient sera binding to acetylcholine receptors and its stability in healthy serum were measured by competitive ELISA. The results showed that the inhibition rate was 2.0-77.4%, and the stability of fusion protein in static healthy sera was about 3 days. This approach suggests the scFv-human serum albumin is a potential candidate for specific immunosuppressive therapy of myasthenia gravis.\n                  <\/jats:p>","DOI":"10.4103\/1673-5374.131611","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T10:05:45Z","timestamp":1415268345000},"page":"851-856","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis"],"prefix":"10.4103","volume":"9","author":[{"given":"Fangfang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanping","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanxin","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhu","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260525","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"R2-20260525","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/bc3002248","article-title":"Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation","volume":"23","author":"Danial","year":"2012","journal-title":"Bioconjug Chem"},{"key":"R3-20260525","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-510X(02)00200-9","article-title":"The role of antibodies in myasthenia gravis","volume":"202","author":"De Baets","year":"2002","journal-title":"J Neurol Sci"},{"key":"R4-20260525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.regpep.2012.01.005","article-title":"Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris","volume":"175","author":"de Bold","year":"2012","journal-title":"Regul Pept"},{"key":"R5-20260525","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s12010-013-0304-1","article-title":"The effect of albumin fusion patterns on the production and bioactivity of the somatostatin-14 fusion protein in Pichia pastoris","volume":"170","author":"Ding","year":"2013","journal-title":"Appl Biochem Biotechnol"},{"key":"R6-20260525","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2011.05.013","article-title":"Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury","volume":"154","author":"Furukawa","year":"2011","journal-title":"J Control Release"},{"key":"R7-20260525","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.158.4.1919","article-title":"Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies","volume":"158","author":"Graus","year":"1997","journal-title":"J Immunol"},{"key":"R8-20260525","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"R9-20260525","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1472-6750-8-50","article-title":"Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin","volume":"8","author":"Huang","year":"2008","journal-title":"BMC Biotechnol"},{"key":"R10-20260525","first-page":"320","article-title":"Single-chain Fv radioimmunotargeting","volume":"40","author":"Huston","year":"1996","journal-title":"Q J Nucl Med"},{"key":"R11-20260525","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00008390-199912000-00003","article-title":"Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments","volume":"9","author":"Kang","year":"1999","journal-title":"Melanoma Res"},{"key":"R12-20260525","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/0008-5472.622.65.2","article-title":"Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments","volume":"65","author":"Kenanova","year":"2005","journal-title":"Cancer Res"},{"key":"R13-20260525","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/protein\/gzq054","article-title":"Tuning the serum persistence of human serum albumin domain III: diabody fusion proteins","volume":"23","author":"Kenanova","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"R14-20260525","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bbrc.2007.02.161","article-title":"Molecular modeling of the complex between Torpedo acetylcholine receptor and anti-MIR Fab198","volume":"356","author":"Konstantakaki","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R15-20260525","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jconrel.2012.03.021","article-title":"Effective transgene expression without toxicity by intraperitoneal administration of PEG-detachable polyplex micelles in mice with peritoneal dissemination","volume":"160","author":"Kumagai","year":"2012","journal-title":"J Control Release"},{"key":"R16-20260525","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3109\/08916930903518099","article-title":"Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis","volume":"43","author":"Lagoumintzis","year":"2010","journal-title":"Autoimmunity"},{"key":"R17-20260525","doi-asserted-by":"crossref","first-page":"368","DOI":"10.18433\/J3H88D","article-title":"Pharmacokinetics and biodistribution of human serum albumin-TIMP-2 fusion protein using near-infrared optical imaging","volume":"14","author":"Lee","year":"2011","journal-title":"J Pharm Pharm Sci"},{"key":"R18-20260525","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pep.2012.05.003","article-title":"Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhIL-2-HSA) fusion protein in Pichia pastoris","volume":"84","author":"Lei","year":"2012","journal-title":"Protein Expr Purif"},{"key":"R19-20260525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s002620050512","article-title":"Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy","volume":"47","author":"Li","year":"1998","journal-title":"Cancer Immunol Immunother"},{"key":"R20-20260525","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1472-6750-12-68","article-title":"Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion","volume":"12","author":"Liu","year":"2012","journal-title":"BMC Biotechnol"},{"key":"R21-20260525","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J Neurosci"},{"key":"R22-20260525","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/08916930290016646","article-title":"Construction and characterization of a single-chain antibody fragment derived from thymus of a patient with myasthenia gravis","volume":"35","author":"Meng","year":"2002","journal-title":"Autoimmunity"},{"key":"R23-20260525","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clineuro.2012.06.013","article-title":"The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis","volume":"115","author":"Nikolic","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"R24-20260525","doi-asserted-by":"crossref","first-page":"e28611","DOI":"10.1371\/journal.pone.0028611","article-title":"PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity","volume":"6","author":"Noberini","year":"2011","journal-title":"PLoS One"},{"key":"R25-20260525","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J Immunol"},{"key":"R26-20260525","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/eji.200526173","article-title":"Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci","volume":"35","author":"Protopapadakis","year":"2005","journal-title":"Eur J Immunol"},{"key":"R27-20260525","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/protein\/gzm020","article-title":"Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life","volume":"20","author":"Schlapschy","year":"2007","journal-title":"Protein Eng Des Sel"},{"key":"R28-20260525","first-page":"181","article-title":"Rapid selection using G418 of high copy number transformants of Pichia pastoris for high-level foreign gene expression","volume":"12","author":"Scorer","year":"1994","journal-title":"Biotechnology (N Y)"},{"key":"R29-20260525","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bc010003g","article-title":"Prolonged in vivo residence times of antibody fragments associated with albumin","volume":"12","author":"Smith","year":"2001","journal-title":"Bioconjug Chem"},{"key":"R30-20260525","doi-asserted-by":"crossref","first-page":"25612","DOI":"10.1074\/jbc.M109.027078","article-title":"Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives","volume":"284","author":"Stork","year":"2009","journal-title":"J Biol Chem"},{"key":"R31-20260525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/10731191003634778","article-title":"Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis","volume":"38","author":"Sun","year":"2010","journal-title":"Artif Cells Blood Substit Immobil Biotechnol"},{"key":"R32-20260525","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2174\/138161212799315830","article-title":"Human serum albumin conjugated biomolecules for cancer molecular imaging","volume":"18","author":"Yang","year":"2012","journal-title":"Curr Pharm Des"},{"key":"R33-20260525","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"R34-20260525","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1248\/bpb.35.280","article-title":"Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice","volume":"35","author":"Zhao","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"R35-20260525","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pep.2012.06.009","article-title":"Expression and purification of recombinant human serum albumin fusion protein with VEGF165b in Pichia pastoris","volume":"85","author":"Zhu","year":"2012","journal-title":"Protein Expr Purif"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01300535-201409080-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:09Z","timestamp":1786735749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.131611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,15]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.4103\/1673-5374.131611","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,15]]},"assertion":[{"value":"2014-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}